• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用Campath-1H实现严重难治性自身免疫性中性粒细胞减少症的持续缓解。

Sustained remission of severe resistant autoimmune neutropenia with Campath-1H.

作者信息

Killick S B, Marsh J C, Hale G, Waldmann H, Kelly S J, Gordon-Smith E C

机构信息

Department of Haematology, St George's Hospital Medical School, London.

出版信息

Br J Haematol. 1997 May;97(2):306-8. doi: 10.1046/j.1365-2141.1997.612718.x.

DOI:10.1046/j.1365-2141.1997.612718.x
PMID:9163593
Abstract

We report the course of a patient with severe autoimmune neutropenia in whom only transient responses occurred with corticosteroids, antilymphocyte globulin and granulocyte-colony stimulating factor, and who was resistant to treatment with azathioprine, cyclosporin and intravenous immunoglobulin. A 10 d course of intravenous Campath-1H monoclonal resulted in a sustained haematological response. The long-lasting effect of Campath-1H may be due to its remarkable ability to induce a profound and prolonged peripheral blood T lymphopenia.

摘要

我们报告了一名患有严重自身免疫性中性粒细胞减少症的患者的病程,该患者使用皮质类固醇、抗淋巴细胞球蛋白和粒细胞集落刺激因子仅出现短暂反应,并且对硫唑嘌呤、环孢素和静脉注射免疫球蛋白治疗耐药。静脉注射Campath-1H单克隆抗体10天的疗程导致了持续的血液学反应。Campath-1H的持久效果可能归因于其诱导深刻且持久的外周血T淋巴细胞减少的显著能力。

相似文献

1
Sustained remission of severe resistant autoimmune neutropenia with Campath-1H.使用Campath-1H实现严重难治性自身免疫性中性粒细胞减少症的持续缓解。
Br J Haematol. 1997 May;97(2):306-8. doi: 10.1046/j.1365-2141.1997.612718.x.
2
The effect of treatment with Campath-1H in patients with autoimmune cytopenias.Campath-1H治疗自身免疫性血细胞减少症患者的疗效。
Br J Haematol. 2001 Sep;114(4):891-8. doi: 10.1046/j.1365-2141.2001.03039.x.
3
CAMPATH-1H in the treatment of autoimmune cytopenias.CAMPATH-1H治疗自身免疫性血细胞减少症。
Cytotherapy. 2001;3(3):189-95. doi: 10.1080/146532401753174133.
4
Campath-1H therapy in refractory ocular inflammatory disease.Campath-1H疗法用于难治性眼部炎症性疾病。
Br J Ophthalmol. 2000 Jan;84(1):107-9. doi: 10.1136/bjo.84.1.107.
5
CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.
J Clin Oncol. 1998 Oct;16(10):3257-63. doi: 10.1200/JCO.1998.16.10.3257.
6
Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H).使用淋巴细胞清除抗体阿仑单抗(CAMPATH-1H)治疗复发性/难治性抗中性粒细胞胞浆抗体相关性血管炎的长期随访
Ann Rheum Dis. 2008 Sep;67(9):1322-7. doi: 10.1136/ard.2007.081661. Epub 2007 Nov 29.
7
Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.人CD52抗体治疗既往治疗过的慢性淋巴细胞白血病的II期多中心研究。慢性淋巴细胞白血病CAMPATH-1H治疗欧洲研究组。
J Clin Oncol. 1997 Apr;15(4):1567-74. doi: 10.1200/JCO.1997.15.4.1567.
8
Remission induced by Campath-1H for thymoma-associated agranulocytosis.Campath-1H诱导胸腺瘤相关粒细胞缺乏症缓解。
Ann Hematol. 2004 Jun;83(6):398-400. doi: 10.1007/s00277-003-0834-7. Epub 2003 Dec 19.
9
Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed.Campath-1H治疗至少一种既往化疗方案失败的T细胞幼淋巴细胞白血病患者。
J Clin Oncol. 2002 Jan 1;20(1):205-13. doi: 10.1200/JCO.2002.20.1.205.
10
CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study.
Arthritis Rheum. 1995 Nov;38(11):1589-94. doi: 10.1002/art.1780381110.

引用本文的文献

1
Phagocytosis of Mature Granulocytes by Bone Marrow Macrophages in an Elderly Man with Adult-Onset Primary Autoimmune Neutropenia.一名成年发病的原发性自身免疫性中性粒细胞减少症老年男性骨髓巨噬细胞对成熟粒细胞的吞噬作用
Hematol Rep. 2022 May 25;14(2):165-171. doi: 10.3390/hematolrep14020024.
2
Successful treatment of refractory idiopathic thrombocytopenic purpura and neutropenia with the monoclonal antibody, rituximab.使用单克隆抗体利妥昔单抗成功治疗难治性特发性血小板减少性紫癜和中性粒细胞减少症。
Indian J Hematol Blood Transfus. 2012 Jun;28(2):114-6. doi: 10.1007/s12288-011-0099-6. Epub 2011 Jul 29.
3
[Alemtuzumab: a further option for treatment of multiple sclerosis].
阿仑单抗:治疗多发性硬化症的又一选择
Nervenarzt. 2012 Apr;83(4):487-501. doi: 10.1007/s00115-011-3393-5.
4
Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy.阿仑单抗治疗 IVIG 依赖性慢性炎症性脱髓鞘性多发性神经病。
J Neurol. 2010 Jun;257(6):913-9. doi: 10.1007/s00415-009-5437-3. Epub 2010 Jan 6.
5
[Possibilities and risks of the monoclonal antibody alemtuzumab as a new treatment option for multiple sclerosis].[单克隆抗体阿仑单抗作为多发性硬化症新治疗选择的可能性与风险]
Nervenarzt. 2009 Apr;80(4):468-74. doi: 10.1007/s00115-009-2681-9.
6
Primary and secondary autoimmune neutropenia.原发性和继发性自身免疫性中性粒细胞减少症。
Arthritis Res Ther. 2005;7(5):208-14. doi: 10.1186/ar1803. Epub 2005 Aug 31.
7
The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.多发性硬化症的治疗机会窗口:来自单克隆抗体疗法的证据。
J Neurol. 2006 Jan;253(1):98-108. doi: 10.1007/s00415-005-0934-5. Epub 2005 Jul 27.